UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 422

Sortiert nach

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial

Journal of thrombosis and haemostasis, 2007-11, Vol.5 (11), p.2178-2185

2007

Link zum Volltext

Verfügbarkeit prüfen

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2013-07, Vol.15 (7), p.613-621

2013

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

Diabetes, obesity & metabolism, 2013-12, Vol.15 (12), p.1154-1160

2013

Link zum Volltext

Verfügbarkeit prüfen

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2013-08, Vol.15 (8), p.721-728

2013

Link zum Volltext

Verfügbarkeit prüfen

Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials

Thrombosis research, 2010-09, Vol.126 (3), p.175-182

2010

Link zum Volltext

Verfügbarkeit prüfen

P344 Efficacité et tolérance de l’empagliflozine chez des patients diabétiques de type 2 jeunes et en surpoids ou obèses avec un taux d’HbA1c ≥ 8

Diabetes & metabolism, 2015-03, Vol.41, p.A121-A121

2015

Link zum Volltext

Verfügbarkeit prüfen

P295 L’empagliflozine améliore les paramètres glycémiques et les facteurs de risques cardio-vasculaires de patients diabétiques (type 2, DT2) : données groupées de quatre études pivots (phase III)

Diabetes & metabolism, 2014-03, Vol.40, p.A97-A97

2014

Link zum Volltext

Verfügbarkeit prüfen

P296 L’empagliflozine (EMPA) augmente les infections génitales (IG) mais non les infections urinaires (IU) dans des données groupées de quatre études pivots de phase III

Diabetes & metabolism, 2014-03, Vol.40, p.A97-A97

2014

Link zum Volltext

Verfügbarkeit prüfen

P284 L’efficacité et la sécurité d’emploi du BI 10773, un nouvel inhibiteur de SGLT-2 (Sodium Glucose cotransporteur de type 2), chez des diabétiques de type 2 insuffisamment contrôlés par la metformine

Diabetes & metabolism, 2012-03, Vol.38, p.A97-A97

2012

Link zum Volltext

Verfügbarkeit prüfen

A note to the simulation of the annual and inter-annual variability of the water budget over the Baltic Sea drainage basin

Meteorology and atmospheric physics, 2001-01, Vol.77 (1-4), p.61-73

Jacob, D.

2001

Link zum Volltext

Verfügbarkeit prüfen

Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer

Thrombosis and haemostasis, 2015, Vol.114 (1), p.150

2015

Link zum Volltext

Verfügbarkeit prüfen

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial

Thrombosis and haemostasis, 2011-04, Vol.105 (4), p.721

2011

Link zum Volltext

Verfügbarkeit prüfen

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial

Nephrology, dialysis, transplantation, 2022-06, Vol.37 (7), p.1317-1329

2022

Link zum Volltext

Verfügbarkeit prüfen

193Qualifying event proximity, cardiovascular risk, and benefit of empagliflozin in patients with type 2 diabetes and stable atherosclerosis in the EMPA-REG OUTCOME trial

European heart journal, 2019-10, Vol.40 (Supplement_1)

2019

Link zum Volltext

Verfügbarkeit prüfen

QUALIFYING EVENT PROXIMITY, CARDIOVASCULAR RISK, AND BENEFIT OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES AND STABLE ATHEROSCLEROSIS IN THE EMPA-REG OUTCOME TRIAL

Canadian journal of cardiology, 2019-10, Vol.35 (10), p.S135-S135

2019

Link zum Volltext

Verfügbarkeit prüfen

Bleeding events with dabigatran or warfarin in patients with venous thromboembolism

Thrombosis and haemostasis, 2016, Vol.115 (2), p.291

2016

Link zum Volltext

Verfügbarkeit prüfen

PATIENT PHENOTYPES AND SGLT-2 INHIBITION IN TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL

Canadian journal of cardiology, 2020-10, Vol.36 (10), p.S71-S71

2020

Link zum Volltext

Verfügbarkeit prüfen

P6270Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease

European heart journal, 2019-10, Vol.40 (Supplement_1)

2019

Link zum Volltext

Verfügbarkeit prüfen

Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalisation in EMPA-REG OUTCOME

Heart, lung & circulation, 2021, Vol.30, p.S221-S222

2021

Link zum Volltext

Verfügbarkeit prüfen

Outcome After Thrombectomy and Intravenous Thrombolysis in Patients With Acute Ischemic Stroke: A Prospective Observational Study

Stroke (1970), 2016-06, Vol.47 (6), p.1584-1592

2016

Link zum Volltext

Verfügbarkeit prüfen

Effect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME Trial

Heart, lung & circulation, 2021, Vol.30, p.S220-S221

2021

Link zum Volltext

Verfügbarkeit prüfen

Qualifying Event Proximity, Cardiovascular Risk, and Benefit of Empagliflozin in Patients with Type 2 Diabetes and Stable Atherosclerosis in the EMPA-REG OUTCOME Trial

Heart, lung & circulation, 2019, Vol.28, p.S314-S314

2019

Link zum Volltext

Verfügbarkeit prüfen

A P hase IIb , randomized, placebo‐controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2013-08, Vol.15 (8), p.721-728

2013

Link zum Volltext

Verfügbarkeit prüfen

Water balance modelling in the Baltic Sea drainage basin - analysis of meteorological and hydrological approaches

Meteorology and atmospheric physics, 2001-01, Vol.77 (1-4), p.45-60

2001

Link zum Volltext

Verfügbarkeit prüfen

A Note on the Energy Flux Across the Earth's Surface

Interactions Between Global Climate Subsystems, 1993, p.21-28

1993

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 422

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(380)
Mit Volltextzugriff
(386)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials

P344 Efficacité et tolérance de l’empagliflozine chez des patients diabétiques de type 2 jeunes et en surpoids ou obèses avec un taux d’HbA1c ≥ 8

P295 L’empagliflozine améliore les paramètres glycémiques et les facteurs de risques cardio-vasculaires de patients diabétiques (type 2, DT2) : données groupées de quatre études pivots (phase III)

P296 L’empagliflozine (EMPA) augmente les infections génitales (IG) mais non les infections urinaires (IU) dans des données groupées de quatre études pivots de phase III

P284 L’efficacité et la sécurité d’emploi du BI 10773, un nouvel inhibiteur de SGLT-2 (Sodium Glucose cotransporteur de type 2), chez des diabétiques de type 2 insuffisamment contrôlés par la metformine

A note to the simulation of the annual and inter-annual variability of the water budget over the Baltic Sea drainage basin

Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial

193Qualifying event proximity, cardiovascular risk, and benefit of empagliflozin in patients with type 2 diabetes and stable atherosclerosis in the EMPA-REG OUTCOME trial

QUALIFYING EVENT PROXIMITY, CARDIOVASCULAR RISK, AND BENEFIT OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES AND STABLE ATHEROSCLEROSIS IN THE EMPA-REG OUTCOME TRIAL

Bleeding events with dabigatran or warfarin in patients with venous thromboembolism

PATIENT PHENOTYPES AND SGLT-2 INHIBITION IN TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL

P6270Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease

Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalisation in EMPA-REG OUTCOME

Outcome After Thrombectomy and Intravenous Thrombolysis in Patients With Acute Ischemic Stroke: A Prospective Observational Study

Effect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME Trial

Qualifying Event Proximity, Cardiovascular Risk, and Benefit of Empagliflozin in Patients with Type 2 Diabetes and Stable Atherosclerosis in the EMPA-REG OUTCOME Trial

A P hase IIb , randomized, placebo‐controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

Water balance modelling in the Baltic Sea drainage basin - analysis of meteorological and hydrological approaches

A Note on the Energy Flux Across the Earth's Surface

Suchergebnisse filtern